Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia**A complete list of participants in the Research Group and Publication Committee appears in the Appendix.

Kashyap, Moti L.; McGovern, Mark E.; Berra, Kathleen; Guyton, John R.; Kwiterovich, Peter O.; Harper, Wayne L.; Toth, Phillip D.; Favrot, Laurence K.; Kerzner, Boris; Nash, Stephen; Bays, Harold; Simmons, Phillip

doi:10.1016/s0002-9149(01)02338-4

Cited by 207 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is considered the most effective agent for raising HDL-C (15 to 35%) and increasing HDL particle size [182]. Niacin significantly lowers TGs (20 to 50%) and LDL-C (5–25%) [123].…”

Section: Treatmentmentioning

confidence: 99%

A Comprehensive Review on Metabolic Syndrome

Kaur¹

2014

Cardiology Research and Practice

1,589

1,246

View full text Add to dashboard Cite

Metabolic syndrome is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Insulin resistance, visceral adiposity, atherogenic dyslipidemia, endothelial dysfunction, genetic susceptibility, elevated blood pressure, hypercoagulable state, and chronic stress are the several factors which constitute the syndrome. Chronic inflammation is known to be associated with visceral obesity and insulin resistance which is characterized by production of abnormal adipocytokines such as tumor necrosis factor α, interleukin-1 (IL-1), IL-6, leptin, and adiponectin. The interaction between components of the clinical phenotype of the syndrome with its biological phenotype (insulin resistance, dyslipidemia, etc.) contributes to the development of a proinflammatory state and further a chronic, subclinical vascular inflammation which modulates and results in atherosclerotic processes. Lifestyle modification remains the initial intervention of choice for such population. Modern lifestyle modification therapy combines specific recommendations on diet and exercise with behavioural strategies. Pharmacological treatment should be considered for those whose risk factors are not adequately reduced with lifestyle changes. This review provides summary of literature related to the syndrome's definition, epidemiology, underlying pathogenesis, and treatment approaches of each of the risk factors comprising metabolic syndrome.

show abstract

“…It is considered the most effective agent for raising HDL-C (15 to 35%) and increasing HDL particle size [182]. Niacin significantly lowers TGs (20 to 50%) and LDL-C (5–25%) [123].…”

Section: Treatmentmentioning

confidence: 99%

A Comprehensive Review on Metabolic Syndrome

Kaur¹

2014

Cardiology Research and Practice

1,589

1,246

View full text Add to dashboard Cite

show abstract

“…Impairment of liver function, increase in creatine phosphokinase (CPK) levels, and more serious complications such as myositis and rhabdomyolysis are more frequent when fibrates are combining used with a statin [9-11]. Many patients have difficulty tolerating niacin because of relatively benign but troublesome adverse events, namely, flushing, and niacin may exacerbate hyperuricemia, glucose intolerance, and hepatic dysfunction when combining with a statin [12-14]. OM3-FAs have been shown their well tolerability as an adjunct to statin therapy in numerous studies [15-17].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-Blind, randomized, placebo-controlled study

Lai

Xuan

et al. 2014

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundPatients with mixed hyperlipidemia usually are in need of combination therapy to achieve low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) target values for reduction of cardiovascular risk. This study investigated the efficacy and safety of adding a new hypolipidemic agent, coenzyme A (CoA) to stable statin therapy in patients with mixed hyperlipidemia.MethodsIn this multi-center, 8-week, double-blind study, adults who had received ≥8 weeks of stable statin therapy and had hypertriglyceridemia (TG level at 2.3-6.5 mmol/L) were randomized to receive CoA 400 U/d or placebo plus stable dosage of statin. Efficacy was assessed by the changes in the levels and patterns of lipoproteins. Tolerability was assessed by the incidence and severity of adverse events (AEs).ResultsA total of 304 patients with mixed hyperlipidemia were randomized to receive CoA 400 U/d plus statin or placebo plus statin (n = 152, each group). After treatment for 8 weeks, the mean percent change in TG was significantly greater with CoA plus statin compared with placebo plus statin (-25.9% vs -4.9%, respectively; p = 0.0003). CoA plus statin was associated with significant reductions in TC (-9.1% vs -3.1%; p = 0.0033), LDL-C (-9.9% vs 0.1%; p = 0.003), and non- high-density lipoprotein cholesterol (-13.5% vs -5.7%; p = 0.0039). There was no significant difference in the frequency of AEs between groups. No serious AEs were considered treatment related.ConclusionsIn these adult patients with persistent hypertriglyceridemia, CoA plus statin therapy improved TG and other lipoprotein parameters to a greater extent than statin alone and has no obviously adverse effect.Trial registrationCurrent Controlled Trials ClinicalTrials.gov ID NCT01928342.

show abstract

“…This is because the herb contains monacolins that resemble the pharmacokinetics of lovastatin which has synergistic effect with niacin. Possible adverse effects include flushing, pruritus, rash, or gastrointestinal adverse events [197]. In particular, hyperlipidemic patients who are generally suffering from CVD and taking conventional anticoagulants and antiplatelet drugs should not ignore the potential risks with TCMs [93].…”

Section: Discussionmentioning

confidence: 99%

A Review on the Traditional Chinese Medicinal Herbs and Formulae with Hypolipidemic Effect

Sham

Chan

Wang

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Hyperlipidemia, characterized by the abnormal blood lipid profiles, is one of the dominant factors of many chronic diseases such as diabetes, obesity, and cardiovascular diseases (CVD). For the low cost, effectiveness, and fewer side effects, the popularity of using traditional Chinese medicine (TCM) to handle hyperlipidemia is increasing and its role in health care has been recognized by the public at large. Despite the importance of TCM herbs and formulations, there is no comprehensive review summarizing their scientific findings on handling hyperlipidemia. This review summarizes the recent experimental and clinical results of nine representative single Chinese herbs and seven classic TCM formulae that could improve lipid profiles so as to help understand and compare their underlying mechanisms. Most of single herbs and formulae demonstrated the improvement of hyperlipidemic conditions with multiple and diverse mechanisms of actions similar to conventional Western drugs in spite of their mild side effects. Due to increasing popularity of TCM, more extensive, well-designed preclinical and clinical trials on the potential synergistic and adverse side effects of herb-drug interactions as well as their mechanisms are warranted. Hyperlipidemic patients should be warned about the potential risks of herb-drug interactions, particularly those taking anticoagulants and antiplatelet drugs.

show abstract

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia**A complete list of participants in the Research Group and Publication Committee appears in the Appendix.

Cited by 207 publications

References 27 publications

A Comprehensive Review on Metabolic Syndrome

A Comprehensive Review on Metabolic Syndrome

Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-Blind, randomized, placebo-controlled study

A Review on the Traditional Chinese Medicinal Herbs and Formulae with Hypolipidemic Effect

Contact Info

Product

Resources

About